Editas Medicine (EDIT) Tops Q3 EPS by 2c

Editas Medicine (NASDAQ: EDIT) reported Q3 EPS of ($0.28), $0.02 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $7.54 million versus the consensus estimate of $4.94 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.

You May Also Be Interested In

• Bessent: We Make A Market Buying Older Bonds
• Oracle (ORCL) call put ratio 2.3 calls to 1 put with a focus on October calls into quarter results
• Activist investor presses Xerox to review financial services arm - Bloomberg